All In Biotech

Drug Trial Radar · NCT05686551

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

301

Actual

Start

Feb 3, 2023

Primary completion

May 14, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).

Conditions

  • Huntington Disease

Interventions

  • TominersenDrug

    Tominersen will be administered at the dose and schedule specified in the protocol.

  • PlaceboDrug

    Matching placebo administered IT, Q16W during the DB period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Period: Incidence and Severity of Adverse Events (AEs), With Severity Determined According to the AE Severity Grading ScaleTime frame: Up to approximately 36 months
  2. DB Period: Change From Baseline in Clinical Laboratory Results - Cerebrospinal Fluid (CSF) White Blood Cell (WBC)Time frame: Baseline visit (Day 1), and Months 4, 8, 9, 12, 16
  3. DB Period: Change From Baseline in Clinical Laboratory Results - CSF ProteinTime frame: Baseline visit (Day 1), and Months 4, 8, 9, 12, 16
  4. DB Period: Change From Baseline in Structural Magnetic Resonance Imaging (MRI) Assessing Any New Abnormalities Including Radiographic Features Consistent With Hydrocephalus and Other Relevant MRI Safety FindingsTime frame: Baseline, Months 4, 8, 12, 16 and up to approximately 36 months
  5. DB Period: Percentage Change From Baseline in Geometric Means of CSF Mutant Huntingtin (mHTT) Protein Levels at Month 9Time frame: Baseline, Month 9
  6. DB Period: Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores (non-U.S. Sites) at 16 MonthsTime frame: Baseline to 16 months
  7. DB Period: Change From Baseline in Total Functional Capacity (TFC) Scores (U.S. Sites) at 16 MonthsTime frame: Baseline to 16 months
  8. OLE Period: Incidence and Severity of AEs, With Severity Determined According to the AE Severity Grading ScaleTime frame: Up to approximately 29 months
  9. OLE Period: Change Over Time in Clinical Laboratory Results - CSF WBCTime frame: Up to approximately 24 months
  10. OLE Period: Change Over Time in Clinical Laboratory Results - CSF ProteinTime frame: Up to approximately 24 months
  11. OLE Period: Change From Baseline in Structural MRI Assessing Any New Abnormalities, Including Radiographic Features Consistent With Hydrocephalus and Other Relevant MRI Safety FindingsTime frame: Up to approximately 29 months

Locations

70 sites in 15 countries. Site status is shown where the registry gives one.

  • Uab Medicine

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California Davis Medical System

    Sacramento, California

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • Georgetown University

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • John Hopkins University School of Medicine

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Dent Neurological Institute

    Amherst, New York

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • EvergreenHealth Investigational Drug Services

    Kirkland, Washington

  • Inland Northwest Research

    Spokane, Washington

  • CINME

    Buenos Aires, Argentina

  • Hospital Ramos Mejía

    CABA, Argentina

  • INEBA

    Capital Federal, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Perron Institute for Neurological and Translational Science

    Nedlands, Western Australia, Australia

  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck

    Innsbruck, Austria

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Montreal Neurological Inst

    Montreal, Quebec, Canada

  • Rigshospitalet, Hukommelsesklinikken

    København Ø, Denmark

  • CHU Angers, Batiement Larrey 2, Neurologie

    Angers, France

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Hopital Henri Mondor

    Créteil, France

  • Hopital Roger Salengro Service de Neurologie

    Lille, France

  • CHU de la Timone - Hopital d Adultes

    Marseille, France

  • Hopital Gui de Chauliac

    Montpellier, France

  • CHU Strasbourg Hpital Hautepierre

    Strasbourg, France

  • CHU toulouse - Hôpital Purpan

    Toulouse, France

  • Uniklinik RWTH Aachen

    Aachen, Germany

  • Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie

    Berlin, Germany

  • St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni

    Bochum, Germany

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.